This is an link to some old info but explains what they believe it can do and what this trial is about
https://www.tri.edu.au/vaccine-herpes-simplex-virus
"A Phase 2 study of vaccine efficacy for reduction of HSV viral shedding and symptomatic disease is underway. There is hope the vaccine will result in a “functional cure”, where the visible disease caused by the virus is reduced or prevented. The vaccine may subsequently be tested for its ability to prevent HSV infection. ....
Over time the trials will be extended to test whether the vaccine also works to prevent the spread of the virus but this type of study takes a long period and must involve lots of people."
The current focus seems to be aimed at the minimum requirements to get a product to market, i.e. it reduces viral shedding - this is good.
To prove and be able to make the claim it is a cure or something that prevents infection would take a much bigger trial and cost a lot more.
Initial market would be - people with the disease who want the symptoms to go away. If they subsequently prove it prevents the disease in uninfected people or is a full cure then it becomes more valuable.
- Forums
- ASX - By Stock
- AVR
- Imagine what's possible - HSV 2
Imagine what's possible - HSV 2, page-91
-
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.15 |
Change
0.000(0.00%) |
Mkt cap ! $291.2M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 12 | $15.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.35 | 88 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 12 | 15.150 |
1 | 760 | 15.000 |
2 | 1651 | 14.950 |
1 | 300 | 14.900 |
1 | 364 | 14.600 |
Price($) | Vol. | No. |
---|---|---|
15.350 | 88 | 1 |
15.700 | 277 | 1 |
15.880 | 250 | 1 |
16.000 | 2100 | 2 |
16.250 | 1000 | 1 |
Last trade - 07.02am 31/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
Day chart unavailable
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online